España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Viridian Therapeutics
VRDN
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$19.30
-0.32
-1.63%
Pre-Market: 4:17 PM EDT
Get Report
Comment
Viridian Therapeutics (VRDN) Forecast
News
Earnings
Viridian Therapeutics (VRDN) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Viridian Therapeutics (NASDAQ:VRDN) Stock
Viridian Therapeutics Stock (NASDAQ: VRDN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, November 14, 2024
HC Wainwright & Co. Maintains Buy on Viridian...
Benzinga Newsdesk
Wednesday, November 13, 2024
In-Depth Examination Of 11 Analyst Recommendations For Viridian Therapeutics
Benzinga Insights
Needham Reiterates Buy on Viridian Therapeuti...
Benzinga Newsdesk
Tuesday, November 12, 2024
Viridian Therapeutics shares are trading high...
Benzinga Newsdesk
Viridian Says Current Cash And Equivalents Wi...
Benzinga Newsdesk
Viridian Therapeutics Q3 2024 GAAP EPS $(1.15...
Benzinga Newsdesk
Monday, October 28, 2024
Analyst Expectations For Viridian Therapeutics's Future
Benzinga Insights
Needham Reiterates Buy on Viridian Therapeuti...
Benzinga Newsdesk
Thursday, September 26, 2024
Forecasting The Future: 13 Analyst Projections For Viridian Therapeutics
Benzinga Insights
Viridian Therapeutics shares are trading high...
Benzinga Newsdesk
BTIG Maintains Buy on Viridian Therapeutics, ...
Benzinga Newsdesk
Thursday, September 19, 2024
RBC Capital Reiterates Outperform on Viridian...
Benzinga Newsdesk
Friday, September 13, 2024
RBC Capital Maintains Outperform on Viridian ...
Benzinga Newsdesk
Thursday, September 12, 2024
Viridian Therapeutics shares are trading high...
Benzinga Newsdesk
Goldman Sachs Maintains Buy on Viridian Thera...
Benzinga Newsdesk
Reported Earlier, Viridian Therapeutics Price...
Benzinga Newsdesk
Wednesday, September 11, 2024
Viridian Therapeutics shares are trading high...
Benzinga Newsdesk
Needham Maintains Buy on Viridian Therapeutic...
Benzinga Newsdesk
Tuesday, September 10, 2024
Viridian Therapeutics Announces $150M Propose...
Benzinga Newsdesk
Critical Insights From Viridian Therapeutics Analyst Ratings: What You Need To Know
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Viridia...
Benzinga Newsdesk
BTIG Maintains Buy on Viridian Therapeutics, ...
Benzinga Newsdesk
Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor
Viridian Therapeutics Discloses 'Exciting' Data From Experimental Thyroid Eye Disease Candidate, Says Data Met High Bars For Efficacy, Safety
Vandana Singh
Market-Moving News for September 10th
Benzinga Newsdesk
Viridian Therapeutics shares are trading high...
Benzinga Newsdesk
Viridian Therapeutics Says Veligrotug (VRDN-0...
Benzinga Newsdesk
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
Monday, September 09, 2024
Viridian Therapeutics shares are trading high...
Benzinga Newsdesk
Viridian Therapeutics To Host Webcast VRDN-00...
Benzinga Newsdesk
Friday, August 30, 2024
Needham Reiterates Buy on Viridian Therapeuti...
Benzinga Newsdesk
Wednesday, August 28, 2024
RBC Capital Reiterates Outperform on Viridian...
Benzinga Newsdesk
Thursday, August 15, 2024
Decoding 6 Analyst Evaluations For Viridian Therapeutics
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Viridia...
Benzinga Newsdesk
Monday, August 12, 2024
Oppenheimer Reiterates Outperform on Viridian...
Benzinga Newsdesk
Thursday, August 08, 2024
Viridian Therapeutics Q2 2024 Adj EPS $(1.02)...
Benzinga Newsdesk
Tuesday, July 30, 2024
Top 3 Health Care Stocks You May Want To Dump This Quarter
Avi Kapoor
Monday, July 29, 2024
Viridian Therapeutics shares are trading high...
Benzinga Newsdesk
Wedbush Reiterates Outperform on Viridian The...
Benzinga Newsdesk
Thursday, July 25, 2024
Viridian Therapeutics Completes Enrollment Of...
Benzinga Newsdesk
Tuesday, July 16, 2024
Expert Ratings For Viridian Therapeutics
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Viridia...
Benzinga Newsdesk
Tuesday, June 11, 2024
Wolfe Research Initiates Coverage On Viridian...
Benzinga Newsdesk
Needham Reiterates Buy on Viridian Therapeuti...
Benzinga Newsdesk
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
Viridian Therapeutics Gives Details About Pha...
Benzinga Newsdesk
Thursday, June 06, 2024
7 Analysts Assess Viridian Therapeutics: What You Need To Know
Benzinga Insights
Goldman Sachs Initiates Coverage On Viridian ...
Benzinga Newsdesk
Thursday, May 09, 2024
HC Wainwright & Co. Maintains Buy on Viridian...
Benzinga Newsdesk
Oppenheimer Maintains Outperform on Viridian ...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch